ARGENX SE - ADR (ARGX) Stock Price, Quote, News and Overview
NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD
ARGX Quote, Performance and Key Statistics
NASDAQ:ARGX (2/20/2025, 1:32:55 PM)
645.34
+5.2 (+0.81%)
The current stock price of ARGX is 645.34 USD. In the past month the price decreased by -1.12%. In the past year, price increased by 56.31%.
ARGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.74 | 353.09B | ||
| AMGN | AMGEN INC | 14.89 | 158.48B | ||
| GILD | GILEAD SCIENCES INC | 23.7 | 136.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1656.83 | 123.44B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.21 | 75.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.29B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.20B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.09B | ||
| NTRA | NATERA INC | N/A | 22.00B | ||
| BIIB | BIOGEN INC | 8.33 | 20.00B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 16.64B |
Related stock screener links
About ARGX
Company Profile
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,148 full-time employees. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Company Info
ARGENX SE - ADR
Laarderhoogtweg 25
Amsterdam NOORD-HOLLAND 4811 AH NL
CEO: Tim Van Hauwermeiren
Employees: 1148
Company Website: https://www.argenx.com/
Investor Relations: https://www.argenx.com/investors
Phone: 31763030
ARGENX SE - ADR / ARGX FAQ
What is the stock price of ARGENX SE - ADR today?
The current stock price of ARGX is 645.34 USD. The price increased by 0.81% in the last trading session.
What is the ticker symbol for ARGENX SE - ADR stock?
The exchange symbol of ARGENX SE - ADR is ARGX and it is listed on the Nasdaq exchange.
On which exchange is ARGX stock listed?
ARGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARGENX SE - ADR stock?
25 analysts have analysed ARGX and the average price target is 670.12 USD. This implies a price increase of 3.84% is expected in the next year compared to the current price of 645.34. Check the ARGENX SE - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARGENX SE - ADR worth?
ARGENX SE - ADR (ARGX) has a market capitalization of 39.21B USD. This makes ARGX a Large Cap stock.
How many employees does ARGENX SE - ADR have?
ARGENX SE - ADR (ARGX) currently has 1148 employees.
What are the support and resistance levels for ARGENX SE - ADR (ARGX) stock?
ARGENX SE - ADR (ARGX) has a support level at 639.84 and a resistance level at 643.55. Check the full technical report for a detailed analysis of ARGX support and resistance levels.
Is ARGENX SE - ADR (ARGX) expected to grow?
The Revenue of ARGENX SE - ADR (ARGX) is expected to grow by 76.75% in the next year. Check the estimates tab for more information on the ARGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARGENX SE - ADR (ARGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARGX, evaluating the profitability, health, valuation and growth aspects
- ARGENX SE - ADR (ARGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARGENX SE - ADR (ARGX) Sales and EPS estimates to see what analysts future expectations are.
- ARGENX SE - ADR (ARGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARGENX SE - ADR (ARGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARGENX SE - ADR (ARGX) Stock Chart to make your own analysis
- ARGENX SE - ADR (ARGX) Latest news and press-releases to stay up to date.
Does ARGENX SE - ADR (ARGX) stock pay dividends?
ARGX does not pay a dividend.
When does ARGENX SE - ADR (ARGX) report earnings?
ARGENX SE - ADR (ARGX) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of ARGENX SE - ADR (ARGX)?
ARGENX SE - ADR (ARGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).
What is the Short Interest ratio of ARGENX SE - ADR (ARGX) stock?
The outstanding short interest for ARGENX SE - ADR (ARGX) is 3.32% of its float. Check the ownership tab for more information on the ARGX short interest.
ARGX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ARGX. When comparing the yearly performance of all stocks, ARGX is one of the better performing stocks in the market, outperforming 89.07% of all stocks.
ARGX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ARGX. While ARGX seems to be doing ok healthwise, there are quite some concerns on its profitability.
ARGX Financial Highlights
Over the last trailing twelve months ARGX reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 78.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.77% | ||
| ROE | -6.5% | ||
| Debt/Equity | 0.01 |
ARGX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to ARGX. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 127.93% and a revenue growth 76.75% for ARGX